Preferred Label : Allogeneic Anti-EGFR Antibody-conjugated Gamma Delta 2 T-cells ACE2016;
NCIt synonyms : Allogeneic Anti-EGFR Antibody-conjugated gd2 T-cells ACE2016 (SY); Allogeneic gd2
T-cells ACE2016; Allogeneic Anti-EGFR Conjugated Gamma Delta 2 T Cells ACE2016; Allogeneic Anti-EGFR T-cells ACE2016; Allogeneic Anti-EGFR Antibody Armed Gamma Delta 2 T-cells ACE2016; Allogeneic EGFR-targeting gd2 T-cells ACE2016;
NCIt definition : An off-the-shelf preparation of a subset of allogeneic T-lymphocytes, derived from
healthy donors, that express only gamma and delta 2 T-cell receptors (TCRs) conjugated,
through antibody cell conjugation (ACC), to an antibody targeting the tumor-associated
antigen (TAA) epidermal growth factor receptor (EGFR), with potential immunomodulating
and antineoplastic activities. The gamma delta 2 T-cells (gd2 T-cells) and the anti-EGFR
antibody were covalently conjugated to selected DNA aptamers that enable DNA hybridization
to generate EGFR-targeting gd2 T-cells. Upon administration of the allogeneic anti-EGFR
antibody-conjugated gd2 T-cells ACE2016, the anti-EGFR antibody targets and binds
to EGFR expressed on tumor cells. The gd2 T-cells secrete interferon-gamma (IFN-g)
and exert direct killing of the EGFR-expressing tumor cells. In addition, these cells
activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against
EGFR-expressing tumor cells. gd2 T-cells play a key role in the activation of the
immune system and do not require major histocompatibility complex (MHC)-mediated antigen
presentation to exert their cytotoxic effect. EGFR, a receptor tyrosine kinase overexpressed
and/or mutated in many tumor cell types, plays a key role in tumor cell proliferation
and tumor vascularization.;
Molecule name : ACE 2016; ACE-2016;
Origin ID : C218467;
concept_is_in_subset
- has_target
